FDA Compounding Crackdown and the Telehealth Shift: Hims & Hers Partners with Novo Nordisk as Supply Stabilizes

FDA Compounding Crackdown and the Telehealth Shift: Hims & Hers Partners with Novo Nordisk as Supply Stabilizes

The regulatory and commercial landscape surrounding compounded GLP-1 medications has undergone a profound structural shift. As the FDA resolves national drug shortages for key active ingredients like semaglutide and tirzepatide, the regulatory window for compounding pharmacies and telehealth platforms is rapidly closing.¹ This has forced major telehealth platforms to abandon their adversarial, compounding-heavy business models and pivot to official distribution partnerships with major pharmaceutical manufacturers.

The Rise and Fall of Telehealth Compounding Loopholes

During the height of the GLP-1 supply crisis, direct-to-consumer telehealth platforms capitalized on a regulatory loophole under Section 503A and 503B of the Federal Food, Drug, and Cosmetic Act. When a drug is on the FDA’s official shortage list, compounding pharmacies are permitted to manufacture "essentially a copy" of the approved drug to meet patient demand. Telehealth giant Hims & Hers Health, Inc. emerged as a leading voice in this space, offering cheap, compounded versions of semaglutide.

However, as Novo Nordisk and Eli Lilly expanded manufacturing capacity, the FDA began systematically resolving the shortages. In late 2024 and early 2025, the FDA officially declared the shortages of tirzepatide and semaglutide injections resolved, initiating a countdown for compounding pharmacies to halt the regular production of copycat drugs. Furthermore, on April 30, 2026, the FDA proposed keeping tirzepatide, semaglutide, and liraglutide off the 503B Bulks List permanently, finding no clinical basis for outsourcing facilities to compound them from bulk substances when FDA-approved versions are available.

The Capitulation and Partnership: Hims & Hers and Novo Nordisk

The legal and regulatory pressure culminated in a major strategic turnaround. In early 2026, Hims & Hers attempted to launch a compounded copycat of the oral pill form of Wegovy (semaglutide). The launch triggered immediate regulatory backlash from the FDA and a patent infringement lawsuit from Novo Nordisk.

Faced with severe enforcement risk and litigation, Hims & Hers capitulated, pulling its compounded GLP-1 pill from the market. On March 9, 2026, the telehealth company announced a landmark "strategic shift" and entered into a partnership with its former adversary, Novo Nordisk, to sell FDA-approved branded medications.

Under the terms of the agreement:

• Hims & Hers ceased selling its unapproved, compounded semaglutide pill.
• Hims & Hers began providing official, limited-scale access to FDA-approved branded semaglutide products—including the diabetes drug Ozempic, injectable Wegovy, and the oral Wegovy pill—at standard telehealth market pricing.
• Novo Nordisk dismissed its patent infringement lawsuit against Hims & Hers, though it reserved the right to refile in the future.

Market and Investment Implications

For telehealth platforms like Hims & Hers (NYSE: HIMS), this shift represents a double-edged sword. While partnering with Novo Nordisk provides long-term regulatory safety, credibility, and access to a reliable supply of branded blockbusters, it also severely compresses margins. Compounded GLP-1s offered telehealth firms exceptionally high gross margins because they purchased cheap bulk active ingredients and priced them at a premium to cash-paying consumers. Branded distribution, by contrast, operates under tight wholesale pricing structures dictated by drugmakers, meaning telehealth platforms must rely on high subscriber volume and ancillary care services to sustain profitability.

For major drugmakers like Novo Nordisk, these partnerships represent a highly effective strategy to capture the cash-pay and high-deductible consumer segments that were previously lost to compounding pharmacies, while maintaining strict control over their intellectual property.